Novel Psychoplastogenic Tropanes for Treating Brain Disorders

Abstract

Researchers at the University of California, Davis have developed non-hallucinogenic compounds with clinically relevant therapeutic efficacy that promote neural growth and plasticity.

Full Description

This technology encompasses non-hallucinogenic psychoplastogens that may have distinct advantages over their hallucinogenic counterparts. These compounds promote neuron growth and can improve neuronal architecture, thereby demonstrating antidepressant, anxiolytic, and anti-addictive effects. These compounds potentially rectify deleterious changes in neuronal structure associated with neuropsychiatric and neurological diseases/disorders without the subjective effects limiting the clinical utility of hallucinogenic compounds.

Applications

• Treatment of neuropsychiatric disorders like depression, anxiety, and addiction. 
• Therapeutic use in neurological diseases associated with altered synaptic connectivity and plasticity.

Features/Benefits

• Non-hallucinogenic properties as compared to their hallucinogenic counterparts. 
• Potential antidepressant, anxiolytic, and anti-addictive effects. 
• Promotion of neuronal growth and improvement of neuronal architecture. 
• Reduces deleterious changes in neuronal structure associated with neuropsychiatric and neurological diseases/disorders. 
• Overcomes the limited clinical utility of hallucinogenic compounds due to their subjective effects. 
• Chemical space is distinct from classic serotonergic psychedelics.

Patent Status

Additional Patent Pending